Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

• Main Authors: Bayarmagnai Weinstein (Author), Bogdan Muresan (Author), Sara Solano (Author), Antonio Vaz de Macedo (Author), YoonJung Lee (Author), Yu-Chen Su (Author), Yeseul Ahn (Author), Gabriela Henriquez (Author), Christina Carmago (Author), Gwang-Jin Kim (Author), David O. Carpenter (Author)
• Formato: Libro
• Publicado: University of Minnesota Libraries Publishing, 2021-11-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the...